Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.

While perhaps best known for historical achievements in immuno-oncology and CNS disorders, the Swiss biotech sector is slowly cultivating a new area of expertise in dermatology. Scrip spoke with two firms applying cell therapy technologies to the challenging area of chronic and acute wounds.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.

Tremendous progress has been made in the field of ablation therapy for atrial fibrillation (AF) over the past several years, and numerous device-based technologies to address this underserved and rapidly growing patient population are under clinical development. Minimally invasive, percutaneous AF ablation has evolved rapidly as well, although the procedure remains very challenging and limited to highly experienced centers.